A joint Ajax Therapeutics Inc. and Dana-Farber Cancer Institute Inc. patent divulges new JAK2 degradation inducers intended for use in the treatment of polycythemia vera, myeloid leukemia and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results